SELP and neoplasm: While ShFCS derivatives exhibit potent P-selectin inhibitory activity in vitro and demonstrate promising potential as anti-tumor and anti-inflammatory therapeutics, their clinical translation faces significant pharmacological challenges, particularly concerning the metabolic stability of sulfate moieties and oral bioavailability.